Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671918 · ClinicalTrials.gov registry record · Phase 3
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
A Phase 3 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
NCT00671918: Completed Phase 3 study, sponsored by Navidea Biopharmaceuticals.
NCT00671918 is a Phase 3 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 186 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671918, a Phase 3 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
Study Summary
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.
Primary Outcome
The proportion of lymph nodes detected intraoperatively by blue dye that were also detected by Lymphoseek.
Interventions
- DRUG Lymphoseek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
What the finished NCT00671918 record still lists
NCT00671918 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which Lymphoseek is the first listed.
NCT00671918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00671918 about?
NCT00671918 is a clinical study titled "Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma". Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.
What is the current status of trial NCT00671918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2008-04. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00671918?
The interventions under investigation include: Lymphoseek (DRUG).
Who is sponsoring clinical trial NCT00671918?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00671918's enrollment target sits among peer trials
186 1412th of 2000 higher than 584 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia